With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of
growth, particularly in Asia.
The latest business developments from across Asia by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
Milestone for silicon anode production facility
vehicles. The company’s second-generation “drop-in” technology allows battery manufacturers to easily integrate higher silicon content into their existing production processes without requiring additional capital expenditure.
Nexeon breaks ground for silcon anode production. Scott Brown pictured 6th from left
Silicon anode materials producer Nexeon has celebrated a ground- breaking ceremony for its fi rst commercial production facility, based in Gunsan South Korea, a milestone that positions the company to deliver supplies of anode materials during 2025.
The company’s silicon anode materials are said to signifi cantly increase the energy density of lithium-ion batteries, a key factor in extending the range, and improve charging performance of electric
“Breaking ground on our fi rst commercial production facility is the culmination of many years of dedication and technical accomplishments by the Nexeon team. It marks a key moment in our growth and refl ects the commercial interest customers have shown in our technology,” said Scott Brown, CEO of Nexeon. “By beginning construction on our fi rst commercial production site, we are on track to deliver the game-changing benefi ts of silicon anode materials to the global battery market.”
The company has partnered with OCI, one of the world’s largest manufacturers of silane outside of China, which both aligns with Nexeon’s sustainability mission and has the capability to scale production alongside the company’s requirements, ensuring a reliable supply of raw materials to meet future growing market demands.
More information online:
ilmt.co/PL/Oveq 62663pr@reply-direct.com
Global partnership to accelerate life science commercialisation
Biointelect, a leading life science consulting fi rm, and CR2O, a premier contract research organisation, have joined forces to offer enhanced end-to-end commercialisation solutions globally. The strategic partnership expands geographical reach and provides comprehensive strategic advice and clinical trial capabilities to clients in Australia, Europe, and the US.
CR2O, headquartered in the Netherlands, will extend Biointelect’s capabilities by introducing clinical trial expertise across the European Union and Australia. In return, CR2O gains access to Biointelect’s strategic product development consultancy and commercialisation profi ciency. This collaboration positions Biointelect and CR2O as frontrunners in delivering innovative end-to-end commercialisation solutions, streamlining project work through every stage of the development cycle.
Leah Goodman, CEO of Biointelect, expressed confi dence that the partnership will fortify clients’ trust and enhance their overall experience, focusing on performance and goal achievement. She highlighted the alliance’s potential to yield greater returns for clients across the entire innovation journey.
CR2O CEO Hadil Es-Sbai emphasised the strategic collaboration’s strength in providing advanced end-to-end commercialisation solutions. Leveraging established relationships and insights, the partnership aims to de-risk the complex journey from bench to bedside for pharmaceutical and biotechnology clients.
Leah Goodman, Biointelect CEO.
Hadil Es-Sbai, CEO CR2O.
The partnership has already attracted interest from universities, government bodies, and life science companies seeking comprehensive, tailored solutions. With shared values underpinning their success, Biointelect and CR2O are poised to leverage their track records in bringing life science innovations to market effi ciently.
More information online:
ilmt.co/PL/MMqX and
ilmt.co/PL/A62x 62262pr@reply-direct.com
Business
Opportunities Asia
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148
